CoChat
Sign Up
Cited by 5,291SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies

Characteristics of SARS-CoV-2 and COVID-19

Open access
Hu, Ben, Guo, Hua, Zhou, Peng, Shi, Zheng-Li·2021·Nature Reviews Microbiology
DOI 10.1038/s41579-020-00459-7PMC PMC7537588
Open this paper in CoChat — free accountOpen PDF

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which threatens human health and public safety. In this Review, we describe the basic virology of SARS-CoV-2, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses. We summarize current knowledge of clinical, epidemiological and pathological features of COVID-19, as well as recent progress in animal models and antiviral treatment approaches for SARS-CoV-2 infection. We also discuss the potential wildlife hosts and zoonotic origin of this emerging virus in detail. In this Review, Shi and colleagues summarize the exceptional amount of research that has characterized acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) since this virus has swept around the globe. They discuss what we know so far about the emergence and virology of SARS-CoV-2 and the pathogenesis and treatment of COVID-19.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41579-020-00459-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 140

  1. [1]Cui J Li F Shi ZL Origin and evolution of pathogenic coronaviruses Nat. Rev. Microbiol. 2019 17 181 192 30531947 PMC7097006
  2. [2]Wu JT Leung K Leung GM Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Lancet 2020 395 689 697 32014114 PMC7159271
  3. [4]Deng SQ Peng HJ Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China J. Clin. Med. 2020 9 575 32093211 PMC7074453
  4. [5]Han Q Lin Q Jin S You L Coronavirus 2019-nCoV: a brief perspective from the front line J. Infect. 2020 80 373 377 32109444 PMC7102581
  5. [6]Zhu N A Novel Coronavirus from patients with pneumonia in China, 2019 N. Engl. J. Med. 2020 382 727 733 31978945 PMC7092803
  6. [7]Gralinski LE Menachery VD Return of the coronavirus: 2019-nCoV Viruses 2020 12 135 31991541 PMC7077245
  7. [8]Jiang S Du L Shi Z An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies Emerg. Microbes Infect. 2020 9 275 277 32005086 PMC7033706
  8. [9]Wu Z McGoogan JM Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention JAMA 2020 323 1239 1242 32091533
  9. [12]Chan JF A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Lancet 2020 395 514 523 31986261 PMC7159286
  10. [13]Chen N Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 2020 395 507 513 32007143 PMC7135076
  11. [14]Wang R Zhang X Irwin DM Shen Y Emergence of SARS-like coronavirus poses new challenge in China J. Infect. 2020 80 350 371 32007524 PMC7126811
  12. [16]Eurosurveillance Editorial Team Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern Euro. Surveill. 2020 25 200131e 32019636 PMC7014669
  13. [17]Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Nat. Microbiol. 2020 5 536 544 32123347 PMC7095448
  14. [18]Fisher D Heymann D Q&A: the novel coronavirus outbreak causing COVID-19 BMC Med. 2020 18 57 32106852 PMC7047369
  15. [21]Dong E Du H Gardner L An interactive web-based dashboard to track COVID-19 in real time Lancet Infect. Dis. 2020 20 533 534 32087114 PMC7159018
  16. [23]Deslandes A SARS-CoV-2 was already spreading in France in late December 2019 Int. J. Antimicrob. Agents 2020 55 106006 32371096 PMC7196402
  17. [24]Lu R Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Lancet 2020 395 565 574 32007145 PMC7159086
  18. [25]Chan JF Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Emerg. Microbes Infect. 2020 9 221 236 31987001 PMC7067204
  19. [26]Anderson KG Rambaut A Lipkin WI Holmes EC Garry RF The proximal origin of SARS-CoV-2 Nat. Med. 2020 26 450 452 32284615 PMC7095063
  20. [27]Coutard B The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade Antiviral Res. 2020 176 104742 32057769 PMC7114094
  21. [28]Zhou H A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein Curr. Biol. 2020 30 2196 2203 32416074 PMC7211627
  22. [30]Su YCF Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2 mBio 2020 11 e01610-20 32694143 PMC7374062
  23. [31]Zhao WM The 2019 novel coronavirus resource Yi Chuan 2020 42 212 221 32102777
  24. [32]Korber B Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus Cell 2020 182 812 827 32697968 PMC7332439
  25. [33]Tang X On the origin and continuing evolution of SARS-CoV-2 Natl Sci. Rev. 2020 7 1012 1023 34676127 PMC7107875
  26. [34]Forster P Forster L Renfrew C Forster M Phylogenetic network analysis of SARS-CoV-2 genomes Proc. Natl Acad. Sci. USA 2020 117 9241 9243 32269081 PMC7196762
  27. [35]Paraskevis D Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event Infect. Genet. Evol. 2020 79 104212 32004758 PMC7106301
  28. [36]Hu D Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats Emerg. Microbes Infect. 2018 7 154 30209269 PMC6135831
  29. [37]Lau SKP Possible bat origin of severe acute respiratory syndrome coronavirus 2 Emerg. Infect. Dis. 2020 26 1542 1547 32315281 PMC7323513
  30. [38]Zhang YZ Holmes EC A genomic perspective on the origin and emergence of SARS-CoV-2 Cell 2020 181 223 227 32220310 PMC7194821
  31. [39]Lam TT Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins Nature 2020 583 282 285 32218527
  32. [40]Xiao K Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins Nature 2020 583 286 289 32380510
  33. [41]Liu P Chen W Chen JP Viral metagenomics revealed Sendai virus and coronavirus infection of Malayan pangolins (Manis javanica) Viruses 2019 11 979 31652964 PMC6893680
  34. [42]Zhang T Wu Q Zhang Z Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak Curr. Biol. 2020 30 1346 1351 32197085 PMC7156161
  35. [43]Shi J Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2 Science 2020 368 1016 1020 32269068 PMC7164390
  36. [44]Oreshkova N SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020 Euro Surveill. 2020 25 2001005 32553059 PMC7403642
  37. [45]Sit THC Infection of dogs with SARS-CoV-2 Nature 2020 10.1038/s41586-020-2334-5 32408337 PMC7606701 · DOI
  38. [46]Zhang Q A serological survey of SARS-CoV-2 in cat in Wuhan Emerg. Microbes Infect. 2020 10.1080/22221751.2020.1817796 32867625 PMC7534315 · DOI
  39. [47]Hoffmann M SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 2020 181 271 280 32142651 PMC7102627
  40. [49]Zhao X Broad and differential animal angiotensin-converting enzyme 2 receptor usage by SARS-CoV-2 J. Virol. 2020 94 e00940-20 32661139 PMC7459545
  41. [50]Shang J Structural basis of receptor recognition by SARS-CoV-2 Nature 2020 581 221 224 32225175 PMC7328981
  42. [51]Walls AC Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell 2020 181 281 292 32155444 PMC7102599
  43. [54]Ou X Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Nat. Commun. 2020 11 1620 32221306 PMC7100515
  44. [57]Lukassen S SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells EMBO. J. 2020 39 e105114 32246845 PMC7232010
  45. [59]Yuan Y Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains Nat. Commun. 2017 8 15092 28393837 PMC5394239
  46. [60]Huang C Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020 395 497 506 31986264 PMC7159299
  47. [61]Mehta P COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 2020 395 1033 1034 32192578 PMC7270045
  48. [62]Wu C Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China JAMA Intern. Med. 2020 180 934 943 32167524 PMC7070509
  49. [63]Liu Y Association between age and clinical characteristics and outcomes of COVID-19 Eur. Respir. J. 2020 55 2001112 32312864 PMC7173682
  50. [64]Tian J Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study Lancet Oncol. 2020 21 893 903 32479790 PMC7259911
  51. [65]Yao XH [A pathological report of three COVID-19 cases by minimal invasive autopsies] Zhonghua Bing Li Xue Za Zhi 2020 49 411 417 32172546
  52. [66]Martines RB Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States Emerg. Infect. Dis. 2020 26 2005 2015 32437316 PMC7454055
  53. [67]Zeng Z Pulmonary pathology of early phase COVID-19 pneumonia in a patient with a Benign lung lesion Histopathology 2020 10.1111/his.14138 32374419 PMC7267508 · DOI
  54. [68]Sun SH A mouse model of SARS-CoV-2 infection and pathogenesis Cell Host Microbe 2020 28 124 133 32485164 PMC7250783
  55. [70]Bao L The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice Nature 2020 583 830 833 32380511
  56. [71]Jiang RD Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2 Cell 2020 182 50 58 32516571 PMC7241398
  57. [72]Lu S Comparison of nonhuman primates identified the suitable model for COVID-19 Sig. Transduct. Target. Ther. 2020 5 157 PMC7434851 32814760
  58. [73]Speranza, E. et al. SARS-CoV-2 infection dynamics in lungs of African green monkeys. Preprint at biorxiv https://www.biorxiv.org/content/10.1101/2020.08.20.258087v1 (2020). PMC7875333 33431511 · DOI
  59. [74]Gu H Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy Science 2020 10.1126/science.abc4730 32732280 PMC7574913 · DOI · Paper page
  60. [75]Munster VJ Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 Nature 2020 585 268 272 32396922 PMC7486227
  61. [76]Yu P Age-related rhesus macaque models of COVID-19 Animal Model Exp. Med. 2020 3 93 97 32318665 PMC7167234
  62. [77]Chan JF Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility Clin. Infect. Dis. 2020 10.1093/cid/ciaa325 32215622 PMC7184405 · DOI
  63. [78]Kim YI Infection and rapid transmission of SARS-CoV-2 in ferrets Cell Host Microbe 2020 27 704 709 32259477 PMC7144857
  64. [79]Richard M SARS-CoV-2 is transmitted via contact and via the air between ferrets Nat. Commun. 2020 11 3496 32641684 PMC7343828
  65. [80]Wang D Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 2020 323 1061 1069 32031570 PMC7042881
  66. [82]Lu X SARS-CoV-2 infection in children N. Engl. J. Med. 2020 382 1663 1665 32187458 PMC7121177
  67. [83]Chen H Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Lancet 2020 395 809 815 32151335 PMC7159281
  68. [84]Vivanti AJ Transplacental transmission of SARS-CoV-2 infection Nat. Commun. 2020 11 3572 32665677 PMC7360599
  69. [85]Giacomelli A Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study Clin. Infect. Dis. 2020 71 889 890 32215618 PMC7184514
  70. [86]Chen T Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study BMJ 2020 368 m1091 32217556 PMC7190011
  71. [87]Yang X Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Lancet Respir. Med. 2020 8 475 481 32105632 PMC7102538
  72. [88]Nishiura H Linton NM Akhmetzhanov AR Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission J. Clin. Med. 2020 9 488 32054045 PMC7073724
  73. [89]Li R Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science 2020 368 489 493 32179701 PMC7164387
  74. [90]Petersen E Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Lancet Infect. Dis. 2020 20 e238 e244 32628905 PMC7333991
  75. [91]Yu P Zhu J Zhang Z Han Y A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period J. Infect. Dis. 2020 221 1757 1761 32067043 PMC7107453
  76. [92]Middleton J Reintjes R Lopes H Meat plants-a new front line in the covid-19 pandemic BMJ 2020 370 m2716 32646892
  77. [93]Joob B Wiwanitkit V COVID-19 and migrant workers: lack of data and need for specific management Public Health 2020 183 64 32405096 PMC7218349
  78. [95]Peiris JS Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Lancet 2003 361 1767 1772 12781535 PMC7112410
  79. [96]Zou L SARS-CoV-2 viral load in upper respiratory specimens of infected patients N. Engl. J. Med. 2020 382 1177 1179 32074444 PMC7121626
  80. [98]Stadnytskyi V Bax CE Bax A Anfinrud P The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission Proc. Natl Acad. Sci. USA 2020 117 11875 11877 32404416 PMC7275719
  81. [99]Meselson M Droplets and aerosols in the transmission of SARS-CoV-2 N. Engl. J. Med. 2020 382 2063 32294374 PMC7179963
  82. [100]van Doremalen N Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1 N. Engl. J. Med. 2020 382 1564 1567 32182409 PMC7121658
  83. [101]Lu CW Liu XF Jia ZF 2019-nCoV transmission through the ocular surface must not be ignored Lancet 2020 395 e39 32035510 PMC7133551
  84. [102]Wu Y Prolonged presence of SARS-CoV-2 viral RNA in faecal samples Lancet Gastroenterol. Hepatol. 2020 5 434 435 32199469 PMC7158584
  85. [103]Kampf G Todt D Pfaender S Steinmann E Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents J. Hosp. Infect. 2020 104 246 251 32035997 PMC7132493
  86. [105]Lu N Cheng KW Qamar N Huang KC Johnson JA Weathering COVID-19 storm: successful control measures of five Asian countries Am. J. Infect. Control 2020 48 851 852 32360746 PMC7189844
  87. [106]Bordi L Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020 Euro Surveill. 2020 25 2000170 32127123 PMC7055037
  88. [107]Chan JF Improved molecular diagnosis of COVID-19 by the Novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens J. Clin. Microbiol. 2020 58 e00310-20 32132196 PMC7180250
  89. [108]Corman VM Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Euro Surveill. 2020 25 2000045 31992387 PMC6988269
  90. [109]Konrad R Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020 Euro Surveill. 2020 25 2000173 32156330 PMC7068163
  91. [110]Lu R Development of a novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2 Virol. Sin. 2020 35 344 347 32239445 PMC7110266
  92. [111]Cordes AK Heim A Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the panther fusion J. Clin. Virol. 2020 125 104305 32143123 PMC7129486
  93. [112]Pan Y Zhang D Yang P Poon LLM Wang Q Viral load of SARS-CoV-2 in clinical samples Lancet Infect. Dis. 2020 20 411 412 32105638 PMC7128099
  94. [113]To KK Consistent detection of 2019 novel coronavirus in saliva Clin. Infect. Dis. 2020 71 841 843 32047895 PMC7108139
  95. [114]Wang W Detection of SARS-CoV-2 in different types of clinical specimens JAMA 2020 323 1843 1844 32159775 PMC7066521
  96. [115]Han H Luo Q Mo F Long L Zheng W SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients Lancet Infect. Dis. 2020 20 655 656 32171389 PMC7271222
  97. [116]Zhang W Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Emerg. Microbes Infect. 2020 9 386 389 32065057 PMC7048229
  98. [117]Li T Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0) Emerg. Microbes Infect. 2020 9 582 585 32172669 PMC7103730
  99. [118]Xie X Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing Radiology 2020 296 E41 E45 32049601 PMC7233363
  100. [119]Kanne JP Chest CT Findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist Radiology 2020 295 16 17 32017662 PMC7233362
  101. [120]Guo L Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Clin. Infect. Dis. 2020 71 778 785 32198501 PMC7184472
  102. [121]To KK Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Lancet Infect. Dis. 2020 20 565 574 32213337 PMC7158907
  103. [122]Wang X The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro Cell Discov. 2020 6 28 32373347 PMC7195821
  104. [123]Zhu Z Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 J. Infect. 2020 81 e21 e23 32283143 PMC7195393
  105. [124]Li Y Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial Med 2020 10.1016/j.medj.2020.04.001 PMC7235585 32838353 · DOI
  106. [125]Lian N Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study Clin. Microbiol. Infect. 2020 26 917 921 32344167 PMC7182750
  107. [126]Kawase M Shirato K van der Hoek L Taguchi F Matsuyama S Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry J. Virol. 2012 86 6537 6545 22496216 PMC3393535
  108. [127]Zhou Y Protease inhibitors targeting coronavirus and filovirus entry Antiviral Res. 2015 116 76 84 25666761 PMC4774534
  109. [128]Wang M Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Cell Res. 2020 30 269 271 32020029 PMC7054408
  110. [129]Yao X In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020 71 732 739 32150618 PMC7108130
  111. [130]Rosenberg ES Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state JAMA 2020 323 2493 2502 32392282 PMC7215635
  112. [131]Geleris J Observational study of hydroxychloroquine in hospitalized patients with Covid-19 N. Engl. J. Med. 2020 382 2411 2418 32379955 PMC7224609
  113. [132]Monteil V Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Cell 2020 181 905 913 32333836 PMC7181998
  114. [133]Tian X Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Emerg. Microbes Infect. 2020 9 382 385 32065055 PMC7048180
  115. [134]Xia S Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Cell Res. 2020 30 343 355 32231345 PMC7104723
  116. [135]Ul Qamar MT Alqahtani SM Alamri MA Chen LL Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants J. Pharm. Anal. 2020 10 313 319 32296570 PMC7156227
  117. [136]Williamson BN Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Nature 2020 585 273 276 32516797 PMC7486271
  118. [137]Grein J Compassionate use of remdesivir for patients with severe Covid-19 N. Engl. J. Med. 2020 382 2327 2336 32275812 PMC7169476
  119. [139]Cai Q Experimental treatment with favipiravir for COVID-19: an open-label control study Engineering 2020 10.1016/j.eng.2020.03.007 PMC7185795 32346491 · DOI
  120. [141]Chen F In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds J. Clin. Virol. 2004 31 69 75 15288617 PMC7128415
  121. [142]de Wilde AH Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture Antimicrob. Agents Chemother. 2014 58 4875 4884 24841269 PMC4136071
  122. [143]Cao B A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 N. Engl. J. Med. 2020 382 1787 1799 32187464 PMC7121492
  123. [144]Hung IF Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet 2020 395 1695 1704 32401715 PMC7211500
  124. [147]Xu X Effective treatment of severe COVID-19 patients with tocilizumab Proc. Natl Acad. Sci. USA 2020 117 10970 10975 32350134 PMC7245089
  125. [148]Diurno F Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience Eur. Rev. Med. Pharmacol. Sci. 2020 24 4040 4047 32329881
  126. [150]Mantlo E Bukreyeva N Maruyama J Paessler S Huang C Antiviral activities of type I interferons to SARS-CoV-2 infection Antiviral Res. 2020 179 104811 32360182 PMC7188648
  127. [151]Sallard E Lescure FX Yazdanpanah Y Mentre F Peiffer-Smadja N Type 1 interferons as a potential treatment against COVID-19 Antiviral Res. 2020 178 104791 32275914 PMC7138382
  128. [152]Park A Iwasaki A Type I and Type III interferons - induction, signaling, evasion, and application to combat COVID-19 Cell Host Microbe 2020 27 870 878 32464097 PMC7255347
  129. [153]Duan K Effectiveness of convalescent plasma therapy in severe COVID-19 patients Proc. Natl Acad. Sci. USA 2020 117 9490 9496 32253318 PMC7196837
  130. [154]Shen C Treatment of 5 critically ill patients with COVID-19 with convalescent plasma JAMA 2020 323 1582 1589 32219428 PMC7101507
  131. [155]Wang C A human monoclonal antibody blocking SARS-CoV-2 infection Nat. Commun. 2020 11 2251 32366817 PMC7198537
  132. [156]Wu Y A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Science 2020 368 1274 1278 32404477 PMC7223722
  133. [157]Zost SJ Potently neutralizing and protective human antibodies against SARS-CoV-2 Nature 2020 584 443 449 32668443 PMC7584396
  134. [158]Shi R A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Nature 2020 584 120 124 32454512
  135. [159]Smith TRF Immunogenicity of a DNA vaccine candidate for COVID-19 Nat. Commun. 2020 11 2601 32433465 PMC7239918
  136. [160]Zhu FC Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet 2020 395 1845 1854 32450106 PMC7255193
  137. [162]Zhu FC Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial Lancet 2020 396 479 488 32702299 PMC7836858
  138. [163]Folegatti PM Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Lancet 2020 396 467 478 32702298 PMC7445431
  139. [165]Xia S Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials JAMA 2020 324 1 10 32789505 PMC7426884
  140. [166]Tang D Comish P Kang R The hallmarks of COVID-19 disease PLoS Pathog. 2020 16 e1008536 32442210 PMC7244094

Cited by

Sorted by citations

Authors
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L.
Affiliations
Chinese Academy of Sciences (CN)
Corresponding author
Shi, Zheng-Li
ORCID
Venue
Nature Reviews Microbiology
Publisher
Springer Science and Business Media LLC
Published
2020-10-06
Volume
19
Issue
3
Pages
141-154
ISSN
  • 1740-1526 (ISSN-L)
  • 1740-1534
DOI
10.1038/s41579-020-00459-7
PMC
PMC7537588
OpenAlex
W3092136311
Cited by
5,291
References
23
Citations by year
2026: 246 · 2025: 507 · 2024: 854 · 2023: 1159 · 2022: 1492 · 2021: 983 · 2020: 43 · 2018: 1 · 2012: 2
FWCI
43.14
Type
journal article
Language
en
Update notices
correction (2022-02-23)
Open access
Licence
Locations
  • Nature Reviews Microbiology (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (31770175)
  • Chinese Academy of Sciences (XDB29010101)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, viral genome, ACE2 receptor, animal models of infection, antiviral therapy, zoonotic origin, wildlife hosts, pathogenesis, clinical features, emerging infectious diseases
MeSH terms
COVID-19, SARS-CoV-2, Age Factors, Animals, Humans, Phylogeny, Zoonoses, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review